Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ventritex evaluating technologies for atrial tachyarrhythmia treatment.

This article was originally published in The Gray Sheet

Executive Summary

VENTRITEX EYEING ATRIAL TACHYARRHYTHMIA MARKET, company President and CEO Frank Fischer told investors Oct. 17 at the UBS Securities life sciences conference in New York City. The Sunnyvale, California-based manufacturer of implantable cardioverter defibrillators used to treat ventricular tachyarrhythmias is "very interested" in pursuing technologies that could treat atrial tachyarrhythmias, Fisher said. "The very same physician that sees patients with ventricular tachyarrhythmias, most or a good portion of their business is in detecting or treating atrial tachyarrhythmias as well."
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004908

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel